STEM CELLS

[Mr. Halsey]

ACTC is setup to run in Jan and Feb.

i like it also.

[RoagTrader]

What do you guys think about CBAI?

[boomer]

What do you guys think about CBAI?

I do not know a lot about that company but it looks beaten down and should run in the first part of the OBama admin. assuming it last that long

http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=cbai&sid=0&o_symb=cbai&x=0&y=0

[boomer]

What do you guys think about CBAI?

I went ahead and placed an order for 150k shares at 0.002 10k filled quickly and the rest is just sitting there

[Stretcher75]

Great job on buying CBAI Boomer, do you have any other stem cell stocks we should be watching. Thanks

[boomer]

Great job on buying CBAI Boomer, do you have any other stem cell stocks we should be watching. Thanks

Maybe ISCO I am in under 0.2 and I am sure pretty much any and all of use can buy at that point or lower

[boomer]

http://www.chicagotribune.com/business/chi-sun-embryonic-stem-cells-gerjan11,0,7894612.story

NEW YORK—The future of controversial research on embryonic stem cells may be riding on the shoulders of Dr. Thomas Okarma, whose company is poised to begin the nation's first human clinical trials.

If Geron Corp.'s trials are successful, it opens the door to new therapies and drug discoveries that many believe the Bush administration stymied. If not, it could put development of potentially life-saving treatments years away, even if President-elect Barack Obama or the new Democratic Congress reverses a policy to allow federal dollars to boost embryonic stem cell research.

"There's a lot riding on it," Dr. John Kessler, director of the Northwestern University Stem Cell Institute, said of Geron's research. "If this trial goes ahead and is not successful, rightly or wrongly, it will be used as a judgment as to whether embryonic stem cell is effective."

It has taken Geron a decade to get this far. The Menlo Park, Calif.-based company has worked tirelessly to develop a spinal cord treatment. Now, Geron is awaiting the regulatory green light to begin trials in spinal cord patients of its embryonic stem cell-derived drug.

There have been hurdles for Geron, including how the company would conduct its trials and the ethical questions and religious opposition to using human embryos.

The biggest hurdle may have been the lack of government funding for stem cell studies. Because there is no federal money for this kind of research, other than through the National Institutes of Health, there has been little movement in the embryonic stem cell arena outside of Geron's privately funded effort.

[boomer]

another stock site pumping stem cells 

Link retired, links to other penny stock sites not allowed.

[boomer]

NIH awards $16.6 million to UC San Diego Researcher for new epigenome center
            
   http://www.eurekalert.org/pub_releases/2009-01/uoc--na011309.php

      
            

Bing Ren, Ph.D., associate professor of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine and head of the Laboratory of Gene Regulation at the Ludwig Institute for Cancer Research, was recently selected as one of four grant recipients in the National Institutes of Health (NIH) Roadmap's Epigenomics Program, an initiative developed to study stable genetic modifications that affect and alter the behavior of genes across the human genome.

The five-year, $16.6 million grant will support The San Diego Epigenome Center at the Ludwig Institute for Cancer Research at UC San Diego, one of four centers in the country called Reference Epigenome Mapping Centers (REMC) as part of an overall five-year, $190 million NIH program. Ren's grant will support interdisciplinary work to comprehensively map elements of the human epigenome, which Ren describes as "like an added dimension to the DNA string."

"The human epigenome is the next frontier of genomic research," said Ren. "Just as the Human Genome Project provided a picture of the sequence of genomes, our work will help create a map of the processes that impact gene regulation – what turns genes on and off – in order to improve our understanding of what drives human development and disease."

The epigenome plays a pivotal role in cellular differentiation, tissue formation and aging by regulating the transcriptional potential of the genome, specifying when and where genes are activated or expressed. Epigenetic processes, such as modifications to DNA-associated proteins called histones, control genetic activity by changing the three-dimensional structure of chromosomes. Diet and exposure to environmental chemicals throughout all stages of human development, among other factors, can cause such epigenetic changes that may turn on or turn off certain genes.

"Such modifications to the genetic blueprint may provide part of the answer to why some people are more susceptible to disease than others," Ren said. "Our hope is that understanding how and when epigenetic processes control genes throughout our lives will lead to more effective ways to prevent and treat disease."

He and colleagues will study aspects of epigenetics that drive differentiation in human embryonic cells (eHSC), including basic mechanisms that determine a cell's self-renewal or that cause these cells to differentiate along specific lineages, such as blood cells or neurons. As a comparison, they will also grow and collect human primary fibroblast cells, a major cell type found in skin and other connective tissue that is easily grown in cell culture.

[hman11]

Looks life GERN might be taking off. It seems to have bounced off of the 4.63 level.

[boomer]

Looks life GERN might be taking off. It seems to have bounced off of the 4.63 level.

I am a big fan of GERN and I own several shares of it / I have not been pumping it  because it is not a true penny but I love that stock

[boomer]

ASTM Seems to have broken it's support line looks like it should drop to .4 at least ( that is a real bummer )    but the others seem to be holding up very well 

[boomer]

http://www.medadnews.com/News/Index.cfm?articleid=597767

VANCOUVER,British Columbia, Jan. 14, 2009-- STEMCELL Technologies Inc (STEMCELL), a leader in the development and manufacture of cell culture media and cell separation products for life science research, is pleased to announce the opening of a new sales and distribution office in Singapore, effective January 12th, 2009. STEMCELL Singapore PTE Ltd is delighted to be offering direct service to our Singapore customers and this rapidly growing market place.


 
With direct service, customers will have immediate access to in-house scientists and the world-renowned STEMCELL technical support. Customers will also benefit from faster delivery times.

[boomer]

http://sev.prnewswire.com/biotechnology/20090114/DC5835214012009-1.html

WASHINGTON, Jan. 14 /PRNewswire-USNewswire/ -- The Coalition for the Advancement of Medical Research (CAMR) today released a white paper, Catalyst For Cures: Embryonic Stem Cell Research, which outlines the views of nine of the nation's leading scientists on the promises and challenges of embryonic stem cell research. In support for the scientific community's call for reversal of the current restrictions on funding for stem cell research, the group also released the results of a national poll conducted this month for CAMR by Opinion Research Corporation indicating that nearly three-quarters (73%) of Americans believe that President-elect Obama should keep his pledge to lift existing federal restrictions on embryonic stem cell research.

Marking the 10th anniversary of the announcements by James Thomson and John Gearhart that each had successfully grown the first human pluripotent stem cell lines in culture, the White Paper proclaims that "with the knowledge gained in the past decade, stem cell research is more promising than ever."

Despite limited funding, scientists have made great strides in using these primary cells to understand what goes wrong in disease and have begun devising promising new therapies for devastating conditions, such as heart disease, spinal cord injury, and diabetes. Conversations with some of the nation's top stem cell researchers -- in academia and industry -- make clear that, with removal of limits on Federal funding, embryonic stem cell research will fulfill its promise in broader ways than originally anticipated.

"It's time for the federal government to support the broad range of stem cell research so that the greatest public benefit can be achieved on the shoulders of the last 10 years' accomplishments," said Amy Comstock Rick, president of CAMR. "We are hopeful that President-elect Obama will deliver on his campaign commitment to lift the current restrictions, and allow scientists to deliver on the promise of embryonic stem cell research."

Catalyst for Cures: Embryonic Stem Cell Research shares experts' viewpoints and assessments of embryonic stem cell research to date, and takes a bold look at where this research might lead in the coming years. Some highlights include:

"I'd be very surprised if, during the course of my scientific career, the next 20 years, we don't have much better therapies for Parkinson's disease, based on the fact that we have these hESC-derived tissues in culture," says James Thomson.

Many scientists have been studying adult stem cells and learning more about their utility and their limitations. So far, adult stem cells have only successfully been used in a very narrow area: blood system reconstitution, including bone marrow transplant, umbilical cord transplant, and peripheral blood transplant. "The argument that there are 60 to 70 diseases that can be cured with adult stem cells was never credible," says Sean Morrison, University of Michigan.

Biotech firms are revving up, focused on toxicity screening and drug development. A few are aggressively pursuing hES cell-based therapies. Big Pharma is also beginning to invest in stem cells. "Embryonic stem cells are a source of cells for predictive toxicology and drug discovery," says consultant and former Novocell executive Melissa Carpenter.

The Paper concludes that, "scientists see great promise in efforts to improve therapies for diabetes, Parkinson's disease, macular degeneration, cancer, spinal cord injuries, and heart disease. The time for removal of restrictions, expanded support, and implementation of relevant oversight guidelines is now."

The full text of Catalyst for Cures: Embryonic Stem Cell Research is available on the CAMR web site at www.camradvocacy.com.

The following researchers and thought leaders contributed to this white paper:

Melissa K. Carpenter, Ph.D., former Vice President of Research and Development at Novocell Inc., and Director of Stem Cell Biology at Geron Corporation; George Daley, M.D., Ph.D., Harvard Medical School; Kevin C. Eggan, Ph.D., Principal Faculty, Harvard Stem Cell Institute; John P. Gearhart, M.D., Director, Institute for Regenerative Medicine at University of Pennsylvania; Ole Isacson, Dr.Med.Sci., Professor of Neurology, Harvard Medical School; Hans Keirstead, Ph.D., Associate Professor, Anatomy and Neurobiology at University of California, Irvine; Douglas A. Melton, Ph.D., Co-director of the Harvard Stem Cell Institute; Sean J. Morrison, Ph.D., Director, University of Michigan Center for Stem Cell Biology; and James Thomson, V.M.D., Ph.D., Director of Regenerative Biology at University of Wisconsin School of Medicine and Public Health.

[boomer]

GERN makes the BBC news / this trial has been delayed for 6 years by the FDA just so they can say embryonic stem cell research has done nothing.

http://news.bbc.co.uk/1/hi/health/7828800.stm